Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-cell Neoplasms

PURPOSE: A phase I study was conducted to determine the dose-limiting toxicities (DLT) and maximally tolerated dose (MTD) for the combination of bortezomib and alvocidib in patients with B cell malignancies (multiple myeloma, indolent and mantle cell lymphoma). EXPERIMENTAL DESIGN: Patients received...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Holkova, Beata, Perkins, E. Brent, Ramakrishnan, Viswanathan, Tombes, Mary Beth, Shrader, Ellen, Talreja, Neha, Wellons, Martha D., Hogan, Kevin T., Roodman, G. David, Coppola, Domenico, Kang, Loveleen, Dawson, Jana, Stuart, Robert K., Peer, Cody, Figg, William D., Kolla, Sarah, Doyle, Austin, Wright, John, Sullivan, Daniel M., Roberts, John D., Grant, Steven
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2011
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3096752/
https://ncbi.nlm.nih.gov/pubmed/21447728
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-2876
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge